Karyopharm Therapeutics is exploring strategic alternatives and potential financing transactions with Centerview Partners to extend its cash runway and maximize stakeholder value. This corporate update follows mixed clinical news, including the failure of its Phase 3 XPORT-EC-042 trial for selinexor in endometrial cancer to meet its primary endpoint, and plans for an August 2026 sNDA submission for accelerated approval of selinexor in myelofibrosis, which is subject to further FDA discussions regarding data for traditional approval conversion.

Werewolf Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026. Concurrently, the company is exploring strategic alternatives, including potential partnerships, to enhance stockholder value, while also evaluating its cash runway and clinical development timelines.

Lisata Therapeutics, Inc. terminated its merger agreement with Kuva Labs Inc. after Kuva failed to obtain sufficient financing for the tender offer. Kuva is obligated to pay Lisata a $2 million termination fee, and Lisata reserves rights to seek further damages. Lisata's Board will now assess strategic options to enhance stockholder value, including reverse mergers, asset sales, or dissolution, with no assurance of a successful outcome.

Organon & Co. is proceeding with its merger with Sun Pharmaceutical Holdings USA, Inc. A lawsuit was filed alleging incomplete disclosures in the definitive proxy statement, seeking to enjoin the stockholder vote. To avoid delays and litigation risks, Organon voluntarily supplemented the proxy statement, denying the claims' merit. The Board continues to evaluate strategic alternatives, including Sun Pharma's proposal, while considering execution risks associated with other options.

NextCure, Inc. announced a definitive merger agreement with Avere Therapeutics, Inc., under which Avere will become a wholly-owned subsidiary and its stockholders will own approximately 98.11% of the combined entity. The transaction includes a private placement financing for Avere, expected to raise at least $150 million, which is a condition for the merger's closing.

Genprex announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 or PD-L1 antibodies for non-small cell and small cell lung cancer. This patent strengthens the company's intellectual property portfolio, providing crucial protection for therapeutic combinations currently being evaluated in the Acclaim-3 clinical trial. This expands on previously granted patents for REQORSA in other major markets.

Soligenix, Inc. received a Nasdaq delisting notice for failing to meet the minimum bid price requirement, with 180 days to regain compliance. Concurrently, the company terminated its HyBryte™ development program for cutaneous T-cell lymphoma following a Phase 3 futility recommendation. Soligenix is now evaluating all strategic options, including M&A opportunities and advancing its other pipeline programs like dusquetide for Behçet’s Disease.

Fulcrum Therapeutics, Inc. has approved a restructuring plan, reducing its workforce by approximately 85% and incurring $4.2 million in charges, following the discontinuation of pociredir for sickle cell disease. Concurrently, Fulcrum has initiated a comprehensive review of strategic alternatives to maximize stockholder value, engaging Leerink Partners LLC as its financial advisor. Potential options include a merger, acquisition, business combination, or sale/licensing of assets.